{"id":963107,"date":"2026-05-14T16:18:30","date_gmt":"2026-05-14T20:18:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-presents-new-preclinical-and-phase-1-translational-data-supporting-bexobrutideg-nx-5948-in-chronic-spontaneous-urticaria-at-the-2026-society-for-investigative-dermatology-annual-m\/"},"modified":"2026-05-14T16:18:30","modified_gmt":"2026-05-14T20:18:30","slug":"nurix-therapeutics-presents-new-preclinical-and-phase-1-translational-data-supporting-bexobrutideg-nx-5948-in-chronic-spontaneous-urticaria-at-the-2026-society-for-investigative-dermatology-annual-m","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-presents-new-preclinical-and-phase-1-translational-data-supporting-bexobrutideg-nx-5948-in-chronic-spontaneous-urticaria-at-the-2026-society-for-investigative-dermatology-annual-m\/","title":{"rendered":"Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting"},"content":{"rendered":"
\n

\n In preclinical studies of CSU, Bexobrutideg demonstrates potent BTK degradation across key immune cell types and enhanced suppression of Fc\u03b5RI-driven pathology versus remibrutinib<\/em>\n <\/p>\n

\n In healthy volunteers, both single- and multiple-ascending-dose oral dosing of bexobrutideg led to rapid and robust BTK degradation in blood and skin<\/em>\n <\/p>\n

\n Phase 1 studies support continued exploration of new tablet formulation in inflammation and immunology indications<\/em>\n <\/p>\n

BRISBANE, Calif., May 14, 2026 (GLOBE NEWSWIRE) — Nurix Therapeutics (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the presentation of new preclinical and Phase 1 translational data highlighting the potential of bexobrutideg (NX-5948), the company\u2019s wholly owned Bruton\u2019s tyrosine kinase (BTK) degrader, in chronic spontaneous urticaria (CSU). The data are being presented at the 2026 Society for Investigative Dermatology Annual Meeting, taking place May 13\u201316, 2026, in Chicago, Illinois.<\/p>\n

The findings demonstrate that targeted degradation of BTK may provide broader and deeper suppression of pathogenic immune signaling than BTK inhibition alone, supporting the future clinical development of bexobrutideg in inflammation and immunology indications.<\/p>\n

\u201cThese data reinforce the potential of targeted protein degradation to deliver a fundamentally different level of control over immune-mediated disease biology,\u201d said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix Therapeutics. \u201cBy catalytically eliminating BTK, rather than transiently inhibiting it, a single molecule of bexobrutideg can degrade thousands of BTK proteins per hour. Importantly, we have demonstrated virtually complete BTK degradation in both blood and skin of healthy volunteers utilizing our new tablet formulation. Bexobrutideg has the potential to provide deeper and more durable suppression of pathogenic signaling, with the goal of delivering meaningful new treatment options for patients with chronic inflammatory diseases.\u201d<\/p>\n

\u201cThe results highlight a categorical advantage of the degrader approach. While BTK inhibitors can only block kinase activity, complete protein removal by bexobrutideg eliminates both kinase and scaffolding functions simultaneously,\u201d said Gwenn M. Hansen, Ph.D., chief scientific officer at Nurix Therapeutics. \u201cIn the context of controlling Fc\u03b5RI-driven mast cell and basophil degranulation, the key drivers of CSU pathology, this translated in preclinical studies into a ~25-fold greater potency compared to remibrutinib while maintaining a highly BTK-selective profile based on global proteomic analyses of more than 8,700 proteins.\u201d<\/p>\n

\n Bexobrutideg Demonstrates Differentiated Activity in Chronic Spontaneous Urticaria<\/strong>
\n
CSU is an autoimmune condition driven by aberrant activation of mast cells and basophils through Fc\u03b5RI signaling, leading to chronic itching and swelling. Both upstream autoantibody production and downstream effector signaling are dependent on BTK, making it a highly relevant therapeutic target.<\/p>\n

Bexobrutideg is an orally bioavailable BTK degrader designed to eliminate the BTK protein through recruitment of the cereblon E3 ligase complex, which efficiently marks the BTK protein for proteasomal degradation, thereby eliminating both the kinase-dependent and scaffolding functions of BTK.<\/p>\n

\n Key Findings<\/strong>\n <\/p>\n